#liquid biopsy market size

[healthcaremarketanalysis]

Liquid Biopsy market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a latest report published by MarketsandMarkets™.

With the increasing incidence & prevalence of cancer worldwide, there's a growing need for effective methods of early detection, therapy selection, monitoring treatment response, and detecting disease recurrence. Liquid biopsies provide a promising solution by enabling clinicians to detect and analyze cancer-related biomarkers more easily and frequently than traditional tissue biopsies. The burgeoning adoption and recognition of liquid biopsy's advantages over traditional biopsy methods are also propelling a robust evolution in liquid biopsy products and services. However, lack of desired sensitivity and specificity in certain liquid biopsy products is likely to restrain the growth of the market.

[renubresearch]

Liquid Biopsy Market is expected to reach US$ 10.08 Billion by 2030

Renub Research has released a report titled “Global Liquid Biopsy Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2030,” which includes market percentage records and a thorough enterprise analysis. This report looks at the global liquid biopsy market’s competition, geographic distribution, and growth potential. Expert Insights: Ask Analyst or Download Full Report…

[marketdevelopment]

Liquid Biopsy Market Latest Innovations, Drivers and Industry Status 2023 to 2030

The Global Liquid Biopsy Market size is expected to grow from USD 1.59 billion in 2022 to USD 7.02 billion by 2030, at a CAGR of 20.4% during the forecast period (2023-2030).

A liquid biopsy is a minimally invasive diagnostic procedure that involves analyzing various biomarkers (such as circulating tumor cells, cell-free DNA, exosomes, and other nucleic acids) found in bodily fluids like blood, urine, or saliva. It's primarily used for the detection and monitoring of diseases, particularly cancer.

Advances in technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and digital PCR have greatly enhanced the sensitivity and specificity of liquid biopsy tests, enabling more accurate detection and monitoring of diseases.

Liquid biopsies have gained particular attention in the field of oncology for early cancer detection, monitoring treatment response, and detecting resistance mutations. They offer a non-invasive alternative to tissue biopsies and can provide real-time information on tumor dynamics.

While oncology remains the primary focus of liquid biopsy applications, researchers and companies have been exploring its potential in other areas such as prenatal testing, infectious disease diagnostics, transplant monitoring, and autoimmune disease detection.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @

https://introspectivemarketresearch.com/request/16300

Updated Version 2024 is available our Sample Report May Includes the:

Scope For 2024

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by Worldwide Market Reports

Leading players involved in the Liquid Biopsy Market include:

Agilent Technologies (United States), Bio-Rad Laboratories, Inc. (United States), Beckman Coulter(United States), Illumina (United States), PerkinElmer (United States), Becton, Dickinson and Company (BD) (United States), Johnson & Johnson (United States), Abbott Laboratories (United States), Cancer Genetics, Inc. (United States), Myriad Genetics, Inc. (United States) 

Moreover, the report includes significant chapters such as Patent Analysis, Regulatory Framework, Technology Roadmap, BCG Matrix, Heat Map Analysis, Price Trend Analysis, and Investment Analysis which help to understand the market direction and movement in the current and upcoming years. 

If You Have Any Query Liquid Biopsy Market Report, Visit:

https://introspectivemarketresearch.com/inquiry/16300

Segmentation of Liquid Biopsy Market:

By Cancer Type

Lung

Breast

Liver

By Circulating Biomarker

Circulating Tumor DNA

Circulating Tumor Cells

By End-User

Hospitals

Laboratories

Government Research Centre

By Regions: -

North America (US, Canada, Mexico)

Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)

Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)

South America (Brazil, Argentina, Rest of SA)

Key Reasons To Invest In Liquid Biopsy Market Report:

To provide a complete structure and a basic overview of the Liquid Biopsy market.

To provide insights into important Liquid Biopsy aspects such as growth trajectory, CAGR value, market share, and revenue analysis.

Assess growth opportunities, threats, market drivers, and associated risks.

To understand the Liquid Biopsy market competition by analysing the top business people along with market profiles, import/export details, revenue, profit, and market shares.

Indicate pricing structure, import/export details, supply chain analysis, SWOT analysis to facilitate key decision-making process.

Analysing emerging Liquid Biopsy market segments and sub-segments to drive ultimate growth, investment analysis, and future growth opportunities.

Understand sources of knowledge, intended research methodology, and important conclusions.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Acquire This Reports: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16300

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assisting our clients to grow and have a successful impact on the market. Our team at IMR is ready to assist our clients to flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, that specializes in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyse extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.

Contact us:

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1-773-382-1047

Email: sales@introspectivemarketresearch.com

[123567-9qaaq9]

Liquid Biopsy Market | BIS Research

In the ever-evolving realm of cancer diagnostics, the ascent of liquid biopsy signifies a paradigm shift towards innovation, non-invasiveness, and personalized medicine. This groundbreaking approach leverages circulating biomarkers in bodily fluids, offering the promise of early cancer detection and continuous treatment monitoring.

Market Overview: With a valuation of $2,508.2 million in 2021, the global liquid biopsy market is on a trajectory for substantial growth, projected to achieve a noteworthy CAGR of 19.83%, reaching $19,066.0 million by 2032. Factors such as the increasing adoption of Next-Generation Sequencing (NGS), advancements in genomics, and a burgeoning demand for personalized medicine are driving this upward trend.

Key Aspects of Liquid Biopsy:

Non-Invasive Detection:

Liquid biopsy provides a non-intrusive alternative to conventional biopsies, enhancing patient comfort and compliance.

Circulating Biomarkers:

Analyzing DNA, RNA, and proteins in bodily fluids offers insights into the genetic profile of cancer, enabling early detection and continuous monitoring.

Early Detection and Treatment Monitoring:

Liquid biopsy facilitates early cancer detection and ongoing treatment monitoring, crucial for enhancing patient outcomes.

Personalized Medicine:

Tailoring treatments based on the genetic profile enables precision medicine, minimizing side effects and optimizing efficacy.

Market Segmentation:

Offering:

Technology:

Workflow:

Circulating Biomarkers:

Indication:

Clinical Application:

Key Drivers:

Non-Invasiveness and Early Detection:

Liquid biopsy's non-intrusive nature enables timely intervention, reducing treatment costs, and improving patient outcomes.

Rising Cancer Incidence:

The global surge in cancer cases propels the demand for accurate and less invasive diagnostics, positioning liquid biopsy as the preferred option.

Advancements in Genomic Research:

Continuous progress in genomic research identifies more cancer-related biomarkers, enriching our understanding of the disease.

Personalized Medicine:

Liquid biopsy enables tailored treatments, aligning with the principles of personalized medicine.

Challenges:

Regulatory Hurdles:

Varying regulatory approval processes pose challenges for market expansion, emphasizing the need for standardized evaluations.

Analytical Validity:

Enhancing the accuracy and reliability of results is crucial for widespread acceptance, necessitating improvements in sensitivity and specificity.

Data Interpretation:

Robust bioinformatics tools are essential for interpreting the extensive data generated by liquid biopsy tests, ensuring seamless clinical implementation.

Future Outlook:

Technological Advancements:

Ongoing technological advancements are poised to enhance test sensitivity and specificity, incorporating next-gen sequencing and digital PCR.

Expanded Clinical Applications:

Liquid biopsy's potential extends beyond cancer, exploring applications in infectious diseases and neurological disorders.

Collaborations and Partnerships:

Increased collaborations among biotech companies, research institutions, and healthcare providers will drive comprehensive liquid biopsy solutions.

Conclusion: The liquid biopsy market is on the brink of substantial growth, spearheading a transformation in cancer diagnostics. As research progresses and technology evolves, addressing regulatory challenges and ensuring analytical validity become imperative. The liquid biopsy market stands as a beacon of hope, guiding us towards more effective and patient-centric cancer care in the ongoing battle against this formidable adversary.

[kirancmi]

Liquid Biopsy Is Estimated To Witness High Growth Owing To Ease Of Use And Non-Invasive Process

Liquid biopsy is a non-invasive alternative to surgical biopsy that analyzes blood samples to diagnose cancer and other diseases. It allows doctors to detect cancer recurrence earlier and monitor treatment effectiveness with simple blood draws, instead of painful tissue biopsies. The global liquid biopsy market includes products and services required for liquid biopsy testing including reagents and kits, instruments, and services. The technology is useful for monitoring disease progression and identifying therapeutic options for advance stage cancer patients.

The global liquid biopsy Market is estimated to be valued at US$ 5.25 Bn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: The global liquid biopsy market is witnessing significant growth owing to the ease of use and non-invasive process of liquid biopsy as compared to traditional tissue biopsy. As liquid biopsy relies on blood draws it eliminates risks associated with surgical biopsies like infection, scarring, and pain. This has increased adoption amongst patients and healthcare providers for early cancer detection and monitoring. Further, ongoing research and development of liquid biopsy technologies especially for detection of multiple cancer types from a single blood draw is also driving market growth. Various players are focused on development of assays and tests with high sensitivity and specificity to detect even minimum traces of circulating tumor DNA (ctDNA) in bloodstream. However, complex regulatory processes and reimbursement challenges remains a restraining factor in market growth. Liquid biopsy is yet to gain approval for screening of early cancer detection from regulatory bodies. Lack of reimbursement policies also hinders widespread clinical adoption. Nevertheless, ongoing approvals and establishment of reimbursement codes is expected to address these challenges in coming years propelling liquid biopsy market growth. SWOT Analysis Strength: The liquid biopsy market offers non-invasive and cost-effective alternatives to tissue biopsy. It can detect multiple types of cancer from a simple blood draw. This reduces risks associated with invasive surgical biopsy procedures. Liquid biopsy also enables longitudinal monitoring of cancer during and after treatment from blood draws. Weakness: Liquid biopsy tests still need improvements to achieve accuracy levels comparable to tissue biopsy. False positive and false negative results are possible challenges. Limited clinical evidence also means liquid biopsy may not be reimbursed or accepted by regulatory agencies for certain clinical uses. Opportunity: The rising cancer burden worldwide generates vast opportunities for liquid biopsy adoption. Early cancer screening and detection is a key growth driver. Liquid biopsy provides hope for precision and personalized cancer monitoring and management. Growing investments in cancer research support liquid biopsy commercialization. Threats: Intellectual property disputes between companies could impact liquid biopsy innovations. Slow regulatory approvals may limit timely commercialization. Established diagnostic procedures pose competition. Reimbursement policies influence market acceptance. Key Takeaways The global liquid biopsy market size is expected to witness high growth. It is estimated to reach a value of US$ 5.25 billion by 2024, registering a CAGR of 6.7% during the forecast period of 2023 to 2030.

North America currently dominates the market due to rising healthcare investments and growing focus on precision medicine in oncology. Asia Pacific is expected to offer lucrative opportunities owing to increasing cancer incidence, growing healthcare expenditure, and expanding biotechnology industry in countries like China and India. Key players

 operating in the liquid biopsy market are BASF SE, Spectrum Chemical Manufacturing Corp., Kudos Chemie Limited, AVT Natural Products, Tianjin Zhong€TMan, Pharmaceutical Company Ltd., Shandong Xinhua Pharma, Aarti Industries Limited, Bakul Group, Taj Pharmaceuticals Limited., and Jilin Shulan Synthetic Pharmaceutical Co. Ltd. The market is fairly consolidated with large corporations having wide geographical presence and strong foothold. However, small players contribute significantly through novel technologies and regional expertise. Strategic collaborations between companies allow leveraging complementary strengths to commercialize new liquid biopsy applications. Overall, the rapidly evolving oncology diagnostics domain presents immense growth potential for liquid biopsy.

Get more insights on this topic: https://www.newsstatix.com/liquid-biopsy-market-industry-insights-trends-liquid-biopsy-market/

Explore more information on this topic, Please visit: https://allmeaninginhindi.com/navigating-the-evolving-landscape-of-enterprise-artificial-intelligence-solutions/

[aishavass]

North America dominated the global liquid biopsy market in 2018, which was closely followed by Europe. However, Asia Pacific is set to grow at a highest...

[desaletushki]

Liquid Biopsy Market Size, Share & Trends Analysis Report, 2030

Liquid Biopsy Market Growth & Trends

The global liquid biopsy market size is expected to reach USD 22.86 billion by 2030, expanding at a CAGR of 12.46% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancer and the growing geriatric population are major drivers expected to fuel market growth. Furthermore, the use of technologically advanced devices for early detection of diseases is one of the key factors driving the market. In addition, the increasing preference for noninvasive treatment procedures will offer lucrative opportunities in the forecast period.

In recent years, cases of cancer have been rising tremendously and the trend is projected to remain the same in the foreseeable future. A significant shift in lifestyle has exposed the global population to this disorder and has resulted in oncogenic factors. For instance, as per the American Cancer Society, in 2022, the number of new cancer cases is expected to reach 1.9 million, leading to 609,360 deaths. Companies are focusing on expanding their business operations in the clinical liquid biopsy space.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market

For instance, in December 2021, Helio Health and Fulgent Genetics announced the launch of the former’s HelioLiver, a new liquid biopsy test for early liver cancer detection. This liquid biopsy test combines serum protein markers and cell-free DNA methylation patterns. Additionally, new research studies are aiding the development of novel liquid biopsy techniques. For instance, in July 2022, the University of Central Florida announced the development of a novel liquid biopsy technique that facilitates early detection using biomarker identification for lung and breast cancer, making the monitoring of conditions easier.

The enhanced interest of players in liquid biopsy and the increasing rate of approval of new products are further accelerating market growth. Moreover, in the past several years, studies have shown a positive outcome of liquid biopsy platforms. Governments and various regulatory bodies have also shown interest in the area by promoting multiple breakthrough devices for the rapid development of this technology. With the high adoption of the technology by various companies, along with the support of government funding and initiatives, the market is expected to grow in the coming years.

Liquid Biopsy Market Report Highlights

The ctDNA segment is projected to hold the largest share in the market owing to its wide use as a biomarker in the detection of cancer using liquid biopsy

The multi-gene-parallel analysis (NGS) technology segment is expected to grow lucratively due to increasing research and development, increasing cancer cases, advancements in technology, and strategic activities by leading companies

North America dominated the global market in 2022, owing to the increasing demand for new technologies, a large pool of key players, the presence of several clinical laboratories, and advanced healthcare infrastructure in the region

Asia Pacific is expected to grow considerably in the future, owing to the rising prevalence of target conditions in the region and the presence of key players

Liquid Biopsy Market Segmentation

Grand View Research has segmented the global liquid biopsy market based on sample type, biomarker, technology, application, end-use, clinical application, product, and region:

Liquid Biopsy Sample Type Outlook (Revenue, USD Billion, 2018 - 2030)

Blood Sample

Others

Liquid Biopsy Biomarker Outlook (Revenue, USD Billion, 2018 - 2030)

Circulating Tumor Cells (CTCs)

Circulating Tumor DNA (ctDNA)

Extracellular Vesicles (EVs)

Others

Liquid Biopsy Technology Outlook (Revenue, USD Billion, 2018 - 2030)

Multi-gene-parallel Analysis (NGS)

Single Gene Analysis (PCR Microarrays)

Liquid Biopsy Application Outlook (Revenue, USD Billion, 2018 - 2030)

Cancer

Lung Cancer

Prostate Cancer

Breast Cancer

Colorectal Cancer

Leukemia 

Gastrointestinal Cancer

Others

Reproductive Health

Others

Liquid Biopsy End-use Outlook (Revenue, USD Billion, 2018 - 2030)

Hospitals and Laboratories

Specialty Clinics

Academic and Research Centers

Others

Liquid BiopsyClinical Application Outlook (Revenue, USD Billion, 2018 - 2030)

Therapy Selection

Treatment Monitoring

Early Cancer Screening

Recurrence Monitoring

Others

Liquid Biopsy Product Outlook (Revenue, USD Billion, 2018 - 2030)

Instruments

Consumables Kits and Reagents

Software and Services

Regional Insights

The North America market for liquid biopsy led with a revenue share of 50.93% in 2022, owing to high cancer prevalence, rapid technological advancements, and growing government initiatives. Moreover, rapid advancements in technology and intense competition between biotechnology companies aided by recent FDA approvals for liquid biopsy tests are among the factors expected to boost regional market growth over the forecast period. For instance, in November 2020, the FDA approved the liquid biopsy NGS-based FoundationOne Liquid CDx test for multiple cancers and biomarkers.

On the other hand, Asia Pacific is projected to exhibit the fastest CAGR over the forecast period. Some of the factors contributing to the market growth are improving healthcare infrastructure, a growing population, and a rising number of companies entering the market. Asia Pacific has a large population, along with a high prevalence of cancer. According to Global Cancer Statistics 2020, an estimated one-half of all cases and around 58.3% of deaths occurred in Asia in 2020.

Thus, usage of screening tests for cancer has increased in the past few years, owing to growing government initiatives such as free screening for cervical, breast, & lung cancer, and increased collaborations between governments, research institutes, & companies for the distribution and supply of these tests.

List of Key Players of Liquid Biopsy Market

ANGLE plc

Oncimmune

Guardant Health, Inc.

Myriad Genetics, Inc.

Biocept, Inc.

Lucence Health Inc.

Freenome Holdings, Inc.

Hoffmann-La Roche Ltd.

QIAGEN

Illumina, Inc.

Thermo Fisher Scientific, Inc.

Epigenomics AG

Authoritative Research: https://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market

[businessintelligenceinsightsblog]

As per Business Intelligence Insights (BII) study, the global Liquid Biopsy Market attained revenue growth of USD 2394.10 million in 2021 and it is projected to reach around USD 6365.03 million by 2028, growing at a 17.70 % CAGR.

[maryharrisk5]

Adroit Market Research report on global liquid biopsy market gives a holistic view of the market from 2017 to 2025, which includes factors such as market drivers, restraints, opportunities, and challenges.

[evonnebaker]

North America dominated the global liquid biopsy market in 2018, which was closely followed by Europe. However, Asia Pacific is set to grow at a highest pace through 2025.

[healthcaremarketanalysis]

Liquid Biopsy Market worth $11.3 billion by 2029

Liquid Biopsy Market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a new report by MarketsandMarkets™.

In recent years, there has been substantial growth in the liquid biopsy market. The increasing burden of cancer cases globally has highlighted the urgent requirement for more effective and less invasive diagnostic tools. In this context, liquid biopsy emerges as a highly valuable solution. Unlike traditional tissue biopsies, which often involve invasive procedures and can be associated with discomfort and risks for patients, liquid biopsy offers a non-invasive alternative for detecting and monitoring cancer. Furthermore, these tests can also be used in non-invasive prenatal testing and transplantation medicine. Thus, these advantages are driving the rapid evolution and uptake of liquid biopsy products and services in disease diagnosis, treatment, and monitoring.

Liquid Biopsy Market Trends

Download an Illustrative overview:

Browse in-depth TOC on "Liquid Biopsy Market"

406 - Tables

56 - Figures

343 - Pages

In 2023, the assay kits segment held the largest share of the liquid biopsy market by product & service segment.

Based on product & service, the liquid biopsy market has been segmented into assay kits, instruments, and services. The assay kits segment dominated the liquid biopsy market in 2023. The versatility of assay kits contributes to their market dominance. These kits are adaptable to various biomarkers and analytes, accommodating the diverse needs of liquid biopsy applications, from detecting circulating tumor DNA (ctDNA) to monitoring treatment response and disease progression.

The therapy selection segment held the largest share of the liquid biopsy market by clinical application segment in 2023.

Based on clinical applications, the liquid biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring.  In 2023, the largest share of the liquid biopsy market was held by the therapy selection segment. The growth of therapy selection as the major clinical application segment is fueled by the advantages of liquid biopsy over traditional methods with its minimally invasive, real-time monitoring capabilities across various cancer types, its integration into clinical trials and drug development processes, and its cost-effectiveness in guiding therapy selection.

North America is the largest regional market for liquid biopsy market.

The market for liquid biopsy has been divided into six key geographical regions, namely North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2023, North America held the predominant portion of the liquid biopsy market. The region boasts a well-developed healthcare infrastructure, including advanced diagnostic facilities, specialized oncology centers, and a skilled workforce. This infrastructure supports the integration of liquid biopsy into routine clinical practice, facilitating access for patients across various healthcare settings.

Request Sample Pages:

Liquid Biopsy Market Dynamics:

Drivers:

Rising incidence and prevalence of cancer

Cancer awareness initiatives undertaken by global health organizations

Benefits of liquid biopsy over traditional biopsy procedures

Restraints:

Lower sensitivity of certain liquid biopsy procedures

Opportunities:

Growing significance of companion diagnostics

Growth opportunities in emerging countries

Challenge:

Unclear reimbursement scenario

Key Market Players of Liquid Biopsy Industry:

The major players operating in this market are Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Guardant Health (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), Biocept, In. (US), mdxhealth (US), Personalis, Inc. (US), NeoGenomics Laboratories (US), Epigenomics AG (Germany), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences (US), Bio-Techne (US), MedGenome (US), Mesa Labs, Inc. (US), Laboratory Corporation of America Holdings (US), Freenome Holdings, Inc. (US), Strand (India), LungLife AI, Inc. (US), and Lucence Health Inc. (US).

The break-up of the profile of primary participants in the liquid biopsy market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%

Get 10% Free Customization on this Report:

Recent Developments of Liquid Biopsy Industry:

In February 2024, Myriad Genetics, Inc. (US) entered into a definitive agreement to acquire select assets from Intermountain Health. These included assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory.

In January 2024, Natera, Inc. (US) acquired certain assets relating to non-invasive prenatal and carrier screening business from Invitae (US).

In November 2023, Illumina, Inc. (US) launched its TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2.

In April 2023, QIAGEN (Netherlands) launched the QIAseq Targeted cfDNA Ultra Panels, enabling researchers studying cancer and other diseases to turn cell-free DNA (cfDNA) liquid-biopsy samples into libraries ready for NGS in less than eight hours.

In January 2022, Illumina, Inc. (US) partnered with Boehringer Ingelheim (Germany). This partnership was aimed to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

Liquid Biopsy Market - Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall liquid biopsy market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Rising incidence and prevalence of cancer, cancer awareness initiatives undertaken by global health organizations, and increased benefits of liquid biopsy over traditional biopsy procedures), opportunities (Growing significance of companion diagnostics and growth opportunities in emerging countries), restraints (Lower sensitivity of certain liquid biopsy procedures), and challenges (Unclear reimbursement scenario) influencing the growth of the liquid biopsy market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the liquid biopsy market.

Market Development: Comprehensive information about lucrative markets – the report analyses the liquid biopsy market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the liquid biopsy market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), and F. Hoffmann-La Roche Ltd (Switzerland).

[acumenblog]

Breast Cancer Liquid Biopsy Market to Grow with a 22.5% CAGR from 2023 to 2032, Expected to Reach USD 2,495 Million by 2032

Acumen Research and Consulting has recently published a research report on the Breast Cancer Liquid Biopsy Market for the forecast period of 2023 – 2032, wherein, the global market has been analyzed and assessed in an extremely comprehensive manner. The research report on the Breast Cancer Liquid Biopsy Market offers an extensive analysis of how the postoperative pain therapeutics landscape would…

[123567-9qaaq9]

Revolutionizing Cancer Diagnosis: The Evolving Landscape of the Liquid Biopsy Market | BIS Research 

The global liquid biopsy market was estimated to be at $2,508.2 million in 2021, which is expected to grow with a CAGR of 19.83% and reach $19,066.0 million by 2032. The growth in the global liquid biopsy market is expected to be driven by increasing adoption of NGS in various research fields, advancement in NGS, and increase in the adoption of personalized medicine.

Understanding Liquid Biopsy:

Liquid biopsy involves the analysis of biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes, which are released into the bloodstream by cancer cells. This non-invasive method provides valuable insights into the genetic makeup of tumors, allowing for early detection, monitoring of treatment response, and identification of minimal residual disease.

Market Lifecycle Stage

The global liquid biopsy market is still in the nascent phase. Significant increase in the research and development activities pertaining to next-generation sequencing are underway to develop NGS products and services, which are expected to increase due to the rising number of chronic disease burdens such as cancer. Liquid biopsy is a non-invasive medical procedure which holds the ability to detect the presence of molecular cancer biomarkers in biological fluids. The report includes market estimation for tests/services, instruments, kits and consumables used for liquid biopsies of different oncology and non-oncology disorders. Liquid biopsy has a critical role in the precision medicine approach, as it confirms the safe and effective application of targeted therapeutics.

Gain a comprehensive market overview from industry experts and unlock valuable insights to drive your business growth. Download our sample now! @ Liquid Biopsy Market 

Demand – Drivers and Limitations

Following are the demand drivers for the liquid biopsy market:

•    Rising Cancer Prevalence •    Increasing Adoption of Inorganic Growth Strategies in the Market •    Increase in Research Funding from National Cancer Institute

The market is expected to face some limitations too due to the following challenges:

•    Uncertain Reimbursement and Regulatory Policies •    Expected Implementation of Patient Protection and Affordable Care Act in the U.S 

Market Segmentation:

by Offering

by Technology

by Workflow

by Circulating Biomarkers

by Indication

by Clinical Application

by Usage

by End User

by Sample

by Region

Key Players and Competition

The liquid biopsy market is marked by the presence of key players such as Guardant Health, Illumina, Roche Diagnostics, Thermo Fisher Scientific, and Qiagen, among others. These companies are actively engaged in research and development activities to enhance their liquid biopsy technologies, making them more effective in detecting a wide range of cancer types.

Application Across Cancer Types:

Liquid biopsy's versatility is a major factor contributing to its market success. It is not limited to a specific cancer type, making it a valuable tool in the diagnosis and monitoring of various malignancies, including lung, breast, colorectal, prostate, and pancreatic cancers. The ability to analyze genetic mutations specific to each cancer type enhances liquid biopsy's utility across the oncology spectrum.

Challenges and Future Outlook:

While liquid biopsy holds immense promise, it is not without challenges. Standardization of testing methodologies, regulatory approvals, and reimbursement policies are areas that require attention to ensure widespread adoption. Additionally, the constant evolution of cancer genomes poses a challenge in staying ahead with technologies that can effectively detect and analyze these variations.

Looking ahead, the liquid biopsy market is poised for continued growth, with ongoing research and development efforts aimed at improving sensitivity, specificity, and cost-effectiveness. As technology evolves, liquid biopsy is likely to become an integral part of routine cancer care, transforming the landscape of cancer diagnosis and treatment.

Conclusion:

The liquid biopsy market is at the forefront of a revolutionary change in cancer diagnostics, offering a non-invasive and effective alternative to traditional methods. With ongoing advancements in technology, increased awareness, and a growing need for personalized medicine, liquid biopsy is set to play a crucial role in the future of cancer detection and monitoring. As the market continues to expand, collaboration between industry players, healthcare professionals, and regulatory bodies will be essential to overcome challenges and ensure the widespread adoption of this transformative technology.